Linked Life Data

18340360

Source:http://linkedlifedata.com/resource/pubmed/id/18340360

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:18340360rdf:typepubmed:Citationlld:pubmed
pubmed-article:18340360lifeskim:mentionsumls-concept:C0237401lld:lifeskim
pubmed-article:18340360lifeskim:mentionsumls-concept:C0035647lld:lifeskim
pubmed-article:18340360lifeskim:mentionsumls-concept:C1333899lld:lifeskim
pubmed-article:18340360lifeskim:mentionsumls-concept:C0019728lld:lifeskim
pubmed-article:18340360lifeskim:mentionsumls-concept:C0205419lld:lifeskim
pubmed-article:18340360lifeskim:mentionsumls-concept:C1853959lld:lifeskim
pubmed-article:18340360lifeskim:mentionsumls-concept:C0599797lld:lifeskim
pubmed-article:18340360lifeskim:mentionsumls-concept:C1415041lld:lifeskim
pubmed-article:18340360lifeskim:mentionsumls-concept:C0205195lld:lifeskim
pubmed-article:18340360pubmed:issue3lld:pubmed
pubmed-article:18340360pubmed:dateCreated2008-4-23lld:pubmed
pubmed-article:18340360pubmed:abstractTextBirdshot chorioretinopathy (BCR), a chronic ocular inflammatory disease with characteristic choroidal lymphocytic infiltrates, has been strongly associated with human leukocyte antigen (HLA)-A29. Although HLA-A29 occurs frequently in all populations, BCR affects only a small percentage of HLA-A29-positive Caucasians, indicating additional susceptibility factors for BCR. Discovery of HLA class I-specific killer cell immunoglobulin-like receptors (KIR) led to a series of epidemiological studies implicating KIR-HLA gene combinations in disease. Here, we characterized KIR-HLA pairs in BCR patients and controls carrying HLA-A*29 as well as controls lacking HLA-A*29. KIR-HLA pairs implicated for weak inhibition (KIR2DL2/3+HLA-C1 and KIR3DL1+HLA-Bw4(T80)) in combination with activating KIR genes associated with autoimmunity (KIR2DS2, 2DS3 and 2DS4) augment the risk of developing BCR in HLA-A*29-positive individuals. The reciprocal association of strong inhibitory pairs (KIR3DL1+HLA-Bw4(I80) and KIR2DL1+HLA-C2) in combination with those implicated in protection from infection (KIR3DS1+HLA-Bw4(I80) and KIR2DS1+HLA-C2) was observed in HLA-A*29-negative controls. These results suggest that a profound effect of KIR2DS2/S3/S4 in the absence of strong inhibition may enhance the activation of natural killer cells and T-cell subsets against intraocular self-antigens, thereby contributing to pathogenesis of BCR.lld:pubmed
pubmed-article:18340360pubmed:languageenglld:pubmed
pubmed-article:18340360pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18340360pubmed:citationSubsetIMlld:pubmed
pubmed-article:18340360pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18340360pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18340360pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18340360pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18340360pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18340360pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18340360pubmed:statusMEDLINElld:pubmed
pubmed-article:18340360pubmed:monthAprlld:pubmed
pubmed-article:18340360pubmed:issn1476-5470lld:pubmed
pubmed-article:18340360pubmed:authorpubmed-author:MURlld:pubmed
pubmed-article:18340360pubmed:authorpubmed-author:HollandG NGNlld:pubmed
pubmed-article:18340360pubmed:authorpubmed-author:GjertsonD WDWlld:pubmed
pubmed-article:18340360pubmed:authorpubmed-author:ZhaoLLlld:pubmed
pubmed-article:18340360pubmed:authorpubmed-author:RajalingamRRlld:pubmed
pubmed-article:18340360pubmed:authorpubmed-author:TabaruHHlld:pubmed
pubmed-article:18340360pubmed:authorpubmed-author:MonneyCClld:pubmed
pubmed-article:18340360pubmed:authorpubmed-author:DeJJlld:pubmed
pubmed-article:18340360pubmed:authorpubmed-author:BrezinA PAPlld:pubmed
pubmed-article:18340360pubmed:authorpubmed-author:ReedE FEFlld:pubmed
pubmed-article:18340360pubmed:authorpubmed-author:LevinsonR DRDlld:pubmed
pubmed-article:18340360pubmed:authorpubmed-author:CohenJ H MJHlld:pubmed
pubmed-article:18340360pubmed:issnTypeElectroniclld:pubmed
pubmed-article:18340360pubmed:volume9lld:pubmed
pubmed-article:18340360pubmed:ownerNLMlld:pubmed
pubmed-article:18340360pubmed:authorsCompleteYlld:pubmed
pubmed-article:18340360pubmed:pagination249-58lld:pubmed
pubmed-article:18340360pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:18340360pubmed:meshHeadingpubmed-meshheading:18340360...lld:pubmed
pubmed-article:18340360pubmed:meshHeadingpubmed-meshheading:18340360...lld:pubmed
pubmed-article:18340360pubmed:meshHeadingpubmed-meshheading:18340360...lld:pubmed
pubmed-article:18340360pubmed:meshHeadingpubmed-meshheading:18340360...lld:pubmed
pubmed-article:18340360pubmed:meshHeadingpubmed-meshheading:18340360...lld:pubmed
pubmed-article:18340360pubmed:meshHeadingpubmed-meshheading:18340360...lld:pubmed
pubmed-article:18340360pubmed:meshHeadingpubmed-meshheading:18340360...lld:pubmed
pubmed-article:18340360pubmed:meshHeadingpubmed-meshheading:18340360...lld:pubmed
pubmed-article:18340360pubmed:meshHeadingpubmed-meshheading:18340360...lld:pubmed
pubmed-article:18340360pubmed:meshHeadingpubmed-meshheading:18340360...lld:pubmed
pubmed-article:18340360pubmed:meshHeadingpubmed-meshheading:18340360...lld:pubmed
pubmed-article:18340360pubmed:meshHeadingpubmed-meshheading:18340360...lld:pubmed
pubmed-article:18340360pubmed:meshHeadingpubmed-meshheading:18340360...lld:pubmed
pubmed-article:18340360pubmed:meshHeadingpubmed-meshheading:18340360...lld:pubmed
pubmed-article:18340360pubmed:meshHeadingpubmed-meshheading:18340360...lld:pubmed
pubmed-article:18340360pubmed:year2008lld:pubmed
pubmed-article:18340360pubmed:articleTitleCombination of KIR and HLA gene variants augments the risk of developing birdshot chorioretinopathy in HLA-A*29-positive individuals.lld:pubmed
pubmed-article:18340360pubmed:affiliationOcular Inflammatory Disease Center, Jules Stein Eye Institute, David Geffen School of Medicine at UCLA, University of California at Los Angeles, CA 90095-1652, USA.lld:pubmed
pubmed-article:18340360pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:18340360pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:18340360pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
entrez-gene:3105entrezgene:pubmedpubmed-article:18340360lld:entrezgene
entrez-gene:3107entrezgene:pubmedpubmed-article:18340360lld:entrezgene
entrez-gene:3802entrezgene:pubmedpubmed-article:18340360lld:entrezgene
entrez-gene:3806entrezgene:pubmedpubmed-article:18340360lld:entrezgene
entrez-gene:3808entrezgene:pubmedpubmed-article:18340360lld:entrezgene
entrez-gene:3809entrezgene:pubmedpubmed-article:18340360lld:entrezgene
entrez-gene:3811entrezgene:pubmedpubmed-article:18340360lld:entrezgene
entrez-gene:3813entrezgene:pubmedpubmed-article:18340360lld:entrezgene
entrez-gene:100132285entrezgene:pubmedpubmed-article:18340360lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:18340360lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:18340360lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:18340360lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:18340360lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:18340360lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:18340360lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:18340360lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:18340360lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:18340360lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:18340360lld:entrezgene